Pathogens Behind SIBO And Limitations of Rifaximin
Rifaximin, a non-systemic antibiotic, is the standard of care for addressing SIBO [1]. However, it doesn’t work in over 50% of the patients [2]. The fortunate ones get their symptoms reduced but are rarely cured [3]. Further, 64% of the patients who benefit from Rifaximin relapse within a few months [4]. Clearly, a better solution for SIBO is required.
Prior to any serious discussion of potential therapeutic solutions, it is necessary to characterize the small intestinal microbiome and the pathogens behind SIBO. There are relatively few studies that have investigated this because of the technical challenges involved in the intrusive process of extracting duodenal or jejunal aspirate samples. We will highlight the noteworthy ones.
Read more